OVERVIEW
While peanut allergy is the most common cause of food allergy among children in the United States, deaths from accidental peanut exposure are rare. Approximately 80% of individuals who develop peanut allergy early in childhood do not outgrow their allergy and over half of them suffer from additional food allergies. Diagnosis of peanut allergy is made with an unequivocal history of an immediate allergic reaction following peanut ingestion, use of skin prick test and peanut specific IgE levels. Strict allergen avoidance is the standard of care. Peanut (Arachis hypogaea) allergen powder-dnfp is a defatted, slightly roasted peanut flour with a characterized peanut allergen profile and gradually increasing doses are given orally to desensitize patients.

MEDICAL CRITERIA
Not applicable

PRIOR AUTHORIZATION
Not applicable

POLICY STATEMENT
Medicare Advantage Plans
The use of peanut (Arachis hypogaea) allergen powder-dnfp is considered not covered as the evidence is insufficient to determine the effects of the technology on health outcomes.

Commercial Products
The use of peanut (Arachis hypogaea) allergen powder-dnfp is considered not medically necessary as the evidence is insufficient to determine the effects of the technology on health outcomes.

COVERAGE
Benefits may vary between groups and contracts. Please refer to the appropriate Benefit Booklet, Evidence of Coverage or Subscriber Agreement for applicable not medically necessary/not covered benefits/coverage.

BACKGROUND
Peanut allergy is the most common cause of allergy in the United States (U.S.) with an estimated 1.6 million children and teens affected by it. It is also the leading cause of death due to food allergy among teens. However, death from accidental peanut exposure is rare with the risk of death from accidental peanut exposure less than the risk for accidental death in the general population. Data from national food allergy death registry reports less than four deaths per year over the past ten years in the U.S.

Diagnosis
Double-blind, placebo-controlled oral food challenges are the gold standard for the diagnosis of food allergy including peanut. However, food challenge tests for peanut allergy are not performed routinely in a clinical setting due to high-risk of precipitating severe symptoms including anaphylaxis. The diagnosis and management of peanut allergy in clinical practice rely on an unequivocal history of an immediate reaction consisting of typical allergic symptoms following the isolated ingestion of a peanut. After establishing the pretest probability of the diagnosis based on positive clinical history, clinicians measure allergen sensitization with a skin prick test, allergen specific IgE, or both to establish the post-test probability of peanut allergy. The predictive power of
such tests to confirm clinical history has been based on observational studies. Food challenge tests may be
required if the history and IgE test results do not clearly indicate an allergy.

Current Treatment
There are currently no U.S. Food and Drug Administration approved treatments for peanut allergy. The current
standard of care is strict avoidance of peanut-containing food products and timely administration of
epinephrine, antihistamines, beta-blockers, and steroids in case of an allergic reaction upon accidental exposure.
Up to 4 out of 10 individuals with a peanut allergy may experience an accidental exposure with an annual
incidence ranging from 5% to 20%. Neuman-Sunshine et al (2012) retrospectively analyzed records of 572
individuals with peanut allergy. The median age at initial observation was 1.4 years; the median duration of
follow-up was 5.3 years. The rate of post-diagnosis peanut exposure was 4.7%/year; the rate of severe reactions
was 1.6%/year and the use of epinephrine was 1.1%/year. Of the 685 exposures analyzed, 75.9% were due to
ingestion, 13.6% due to contact and 4.5% were airborne. Patients and patient representatives report that strict
avoidance of allergens results in an increased burden of day-to-day living, limitation on social activity and
independence, missed time from work, negative impact on the quality of life and negative emotional impact.
Further, affected persons and their family lifestyles are heavily impacted by fear and anxiety, and an important
goal for patients is to be able to live and eat more freely.

Oral immunotherapy (OIT) is practiced in the U.S. either under clinical trial protocols at tertiary centers or at
unregulated private clinics. The extent of their use is not known and non-reimbursable. According to the
Institute for Clinical and Economic Review, the majority of allergists do not offer oral immunotherapy. As a
result, patients who pursue it often pay out of pocket, which can limit access to those who can afford it. There
have been many studies of oral immunotherapy for peanut allergy using different peanut preparations, different
dose escalation strategies, different maintenance doses (125 mg to 5000 mg peanut protein per day), different
primary outcomes and different target populations.

Allergic reactions can range from mild cutaneous symptoms to gastrointestinal symptoms such as abdominal
pain, nausea, vomiting, and diarrhea and severe reactions such as anaphylaxis. Approximately 80% of
individuals who develop peanut allergy early in childhood do not outgrow their food allergy in adulthood and
over half of them suffer from additional food allergies. For individuals who are peanut-allergic children and
adolescents ages 4 to 17 who receive peanut (Arachis hypogaea) allergen powder-dnfp, the evidence includes
one pivotal double-blind randomized, placebo-controlled trial in which 555 patients aged 4 to 55 years were
randomized to peanut (Arachis hypogaea) allergen powder-dnfp (n=416) or placebo (n=139). A subset of 499
patients aged 4 to 17 years old were used for the primary analysis. Relevant outcomes are symptoms, quality of
life, hospitalizations, medication use, and treatment-related mortality and morbidity. The primary outcome was
the difference in the proportion of participants who could ingest 600 mg or more of peanut protein without
dose-limiting symptoms in a food challenge after approximately one-year follow-up between the treatment and
placebo arm. The percentage of patients who met the primary endpoint at exit food challenge test was 67.2% vs
4.0% (difference 63.2% [95% confidence interval: 53.0 to 73.3], p<0.001) in the AR101 treated arm vs
placebo respectively. Adverse events occurred with greater frequency and severity in peanut (Arachis hypogaea)
allergen powder-dnfp treated individuals vs placebo; serious adverse events (2.2% vs 0.8%), systemic allergic
reactions (14.2% vs 3.2%), use of epinephrine outside of food challenge test (14.0% vs 6.5%), withdrawal due
to adverse events (11.6% vs 2.4%) and overall withdrawal rate (21.0% vs 7.3%). Notable study relevance
limitations include; intended use for the population is unclear, key health outcomes were not addressed (critical)
and not sufficient duration for benefits and not sufficient duration for harms. Key limitations in study design
and conduct include the potential for partial unblinding due to adverse events (outcome assessed by treating
physician). There is need for data to demonstrate that desensitization leads to reduced reactions to accidental
exposure to peanuts and improved quality of life. The evidence is insufficient to determine the effects of the
technology on health outcomes.
CODING
Medicare Advantage Plans and Commercial Products
There is no specific CPT code for treatment using Palforzia (Peanut [Arachis hypogaea] Allergen Powder-dfnp). Claims should be filed using the unlisted HCPCS code:

J8499  Prescription drug, oral, non chemotherapeutic, NOS

RELATED POLICIES
Not applicable

PUBLISHED
Provider Update, April 2021

REFERENCES: